Ipsen acquired OctreoPharm to strengthen its Oncology presence
Ipsen is determined to increase its presence in the oncology field, by acquiring OctreoPharm Sciences.…
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportIpsen is determined to increase its presence in the oncology field, by acquiring OctreoPharm Sciences.…
PsiOxus Therapeutics has closed a Series C financing round of €34.7M (£25 million) to progress…
Baxter has purchased Sigma-Tau’s portfolio of cancer treatments for €793.5M ($900 million). With this important…
Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five…
Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right…
Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from…
Natural killers are an emerging approach to fight inflammatory diseases and cancer. These immune actors,…
Lunaphore Technologies closed a Series A financing round of €1.9M (CHF 2 millions). The round…
France-based PEP-Therapy has raised €1.3M in initial funding. This sum, invested by the Quadrivium 1…
Results from a new global survey of lung cancer oncologists have shown that, despite 81%…
Sysmex Inostics have signed an exclusive distributor agreement with IndivuTest, and its parent company Indivumed,…
Erytech strengthed its intellectual property portfolio in the United States with the granting of a…